Opportunistic Infections
14
2
3
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.1%
1 terminated out of 14 trials
90.0%
+3.5% vs benchmark
14%
2 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
T Cell Therapy of Opportunistic Cytomegalovirus Infection
Re-engagement at Discharge 2
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
Vicente Ferrer HIV Cohort Study
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities
Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria
Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance